Investors must take note of Revance Therapeutics Inc.’s (RVNC) performance last week, which was -3.22%.


September 22, 2022, Revance Therapeutics Inc. (NASDAQ: RVNC) trading session started at the price of $25.95, that was -0.93% drop from the session before. During the day, the shares moved up to $26.10 and dropped to $24.3557 before settling in for the closing price of $25.80. A 52-week range for RVNC has been $11.27 – $30.00.

Top 5 Tech Stocks Every Investor Should Buy Right Now

While finding excellent stocks with the potential for gains isn't always easy, we've found a few that could pay out well. In fact, within our report, "Top 5 Tech Stocks Every Investor Should Buy Right Now", we have identified five tech stocks we believe could appreciate.

Sign up here to get your free report now.


It was noted that within the last five years, the titan of the Healthcare sector saw sales topped by 203.90%. When this article was written, the company’s average yearly earnings per share was at 14.30%. With a float of $78.62 million, this company’s outstanding shares have now reached $81.12 million.

The extent of productivity of a business whose workforce counts for 495 workers is very important to gauge. In terms of profitability, gross margin is +44.39, operating margin of -353.06, and the pretax margin is -361.59.

Revance Therapeutics Inc. (RVNC) Insider and Institutional Ownership

Also, it is sometimes useful to examine the sentiment of large-scale investors toward Revance Therapeutics Inc. stocks. The insider ownership of Revance Therapeutics Inc. is 1.60%, while institutional ownership is 85.50%. The most recent insider transaction that took place on Sep 14, was worth 297,798. In this transaction SVP, GC & Secretary of this company sold 11,000 shares at a rate of $27.07, taking the stock ownership to the 31,694 shares. Before that another transaction happened on Dec 13, when Company’s Director bought 6,400 for $15.74, making the entire transaction worth $100,741. This insider now owns 26,913 shares in total.

Revance Therapeutics Inc. (RVNC) Latest Financial update

Going through the last 3-months fiscal report unveiled on the 6/29/2022, it has been observed that the corporation posted -$0.88 earnings per share (EPS) during the time that was less than consensus figure (set at -$0.86) by -$0.02. This company achieved a net margin of -361.59 while generating a return on equity of -127.07. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.89 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 14.30% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 11.60% during the next five years compared to -5.60% drop over the previous five years of trading.

Revance Therapeutics Inc. (NASDAQ: RVNC) Trading Performance Indicators

You can see what Revance Therapeutics Inc. (RVNC) is doing with its current performance indicators. In the most recent quarter, the stock posted a quick ratio of 3.20. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 21.26.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.84, a number that is poised to hit -0.91 in the next quarter and is forecasted to reach -2.92 in one year’s time.

Technical Analysis of Revance Therapeutics Inc. (RVNC)

The latest stats from [Revance Therapeutics Inc., RVNC] show that its last 5-days average volume of 1.68 million was superior to 0.88 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 32.57%. Additionally, its Average True Range was 1.57.

During the past 100 days, Revance Therapeutics Inc.’s (RVNC) raw stochastic average was set at 78.34%, which indicates a significant increase from 58.38% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 106.52% in the past 14 days, which was higher than the 78.21% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $20.56, while its 200-day Moving Average is $16.68. Now, the first resistance to watch is $26.32. This is followed by the second major resistance level at $27.08. The third major resistance level sits at $28.07. If the price goes on to break the first support level at $24.58, it is likely to go to the next support level at $23.59. The third support level lies at $22.83 if the price breaches the second support level.

Revance Therapeutics Inc. (NASDAQ: RVNC) Key Stats

There are 73,106K outstanding shares of the company, which has a market capitalization of 2.11 billion. As of now, sales total 77,800 K while income totals -281,310 K. Its latest quarter income was 28,370 K while its last quarter net income were -61,440 K.


Please enter your comment!
Please enter your name here